#USA #liver cancer #Woburn #Sirtex Medical #SIR-Spheres

Sirtex Medical's Groundbreaking DOORwaY90 Study

In a significant advancement for cancer treatment, Sirtex Medical has released transformative results from its DOORwaY90 clinical trial, marking a new standard in the therapy for unresectable hepatocellular carcinoma (HCC) using Y-90 selective internal radiation therapy (SIRT).

Overview of the DOORwaY90 Study

Conducted over a span of 12 months, the DOORwaY90 study stands out as the first pivotal, prospective, multi-center clinical trial in the United States focusing on the application of Y-90 therapy through precision dosimetry for patients who cannot undergo surgical intervention due to the advanced stage of their liver cancer. This innovative approach utilizes SIR-Spheres® as a treatment tool, illustrating a pioneering path in the realm of interventional oncology.

The study achieved impressive outcomes, reporting a 99% overall response rate (ORR) based on blinded independent central review, and an astonishing 100% local tumor control rate. To add to this, the study indicated a remarkable 90% rate of complete response (CR) among patients assessed, highlighting the effectiveness of the treatment methodology employed. Notably, these results underscore one of the highest recorded response rates in Y-90 therapies administered to HCC patients.

Durability of Treatment Effects

Among the patients who responded favorably to the treatment, 75% maintained their responses beyond six months, with the median duration of response clocking in at an impressive 295 days. This durability signifies the potential of SIR-Spheres Y-90 microspheres in providing sustained tumor response while simultaneously preserving liver functionality, a crucial aspect given the vulnerable condition of HCC patients.

Moreover, over 95% of these patients exhibited stable liver function after completing the 12-month follow-up period. This is a testament to the personalized dosimetry approach that effectively induces robust anti-tumor responses without compromising liver reserves—a critical factor in the overall treatment strategy.

Expert Insights

Dr. Armeen Mahvash, a leading interventional radiologist at MD Anderson Cancer Center and one of the principal investigators of the DOORwaY90 trial, commented on the findings, stating, "These 12-month results showcase the reproducibility of responses achievable through personalized dosimetry. The high rate of complete responses, their durability, and the preservation of liver function observed in this study enhances physician confidence in utilizing radioembolization as a targeted, locoregional treatment for liver cancer."

Matt Schmidt, President of Sirtex Medical, also weighed in, saying, "The results set a new standard of expectation for Y-90 therapies. With an overall response rate of 99% and a 100% tumor control rate, the DOORwaY90 trial demonstrates that personalized dosimetry using SIR-Spheres can deliver results that challenge traditional approaches and broaden treatment facets for patients with unresectable HCC."

About SIR-Spheres® Y-90

SIR-Spheres® Y-90 microspheres hold the distinction of being the only FDA-approved radioembolization therapy aimed at treating both metastatic colorectal cancer in the liver and unresectable hepatocellular carcinoma in the United States. These microspheres are specifically indicated for local tumor control in patients with HCC lacking macrovascular invasion and are crucial for patients with well-compensated liver function according to the Child-Pugh classification.

Given the promising results from the DOORwaY90 study, which includes compelling safety and efficacy profiles, deploying SIR-Spheres® in clinical practices emerges as a potent avenue for enhancing patient outcomes. As Sirtex continues to innovate within the realm of oncological interventions, engagement with healthcare providers can lead to significant advancements in the battle against liver cancer.

For more insights on integrating SIR-Spheres® into clinical practice or further inquiries, healthcare professionals can reach Sirtex directly at [email protected].

Conclusion

The advancements highlighted by the DOORwaY90 study underscore a pivotal moment in oncological therapies. By offering a combination of high efficacy and minimal adverse effects, SIR-Spheres® Y-90 establishes a crucial therapeutic option for patients who face limited treatment avenues, driving progress in the fight against liver cancer.